Posted by Michael Wonder on 12 Feb 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis)
11 February 2020 - Eli Lilly Canada announced today that Health Canada approved Taltz (ixekizumab) on 4 February 2020, for the treatment of adult patients with active ankylosing spondylitis, which is also known as radiographic axial spondyloarthritis, who have responded inadequately to, or are intolerant to, conventional therapy.
This is the third indication for Taltz, which was first approved by Health Canada for moderate- to severe plaque psoriasis and psoriatic arthritis in 2016 and 2018, respectively.
The efficacy and safety of Taltz was demonstrated in two randomized, double-blind, placebo-controlled Phase 3 studies that included 657 adult patients with active AS: COAST-V in patients who are biologic disease-modifying antirheumatic drug (bDMARD)-naïve, and COAST-W in patients who previously had an inadequate response or were intolerant to tumor necrosis factor inhibitors.
